CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06128044 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision - Pipeline Reprioritization

Conditions

Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory

Interventions

DRUG: CB-012

Sponsor

Caribou Biosciences, Inc.